发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
:L-DOPA-induced dyskinesia (LID) is a major complication of long-term dopamine replacement therapy in Parkinson's disease. Characteristic neural oscillation and abnormal activity of striatal projection neurons (SPNs) are typical pathological events of LID, which would be reliable biomarkers for assessment of novel anti-dyskinetic approach if fully profiled. Glutamate dysregulation plays a critical role in the development of LID, and the group II metabotropic glutamate receptors (mGluR2/3) is believed to regulate the release of glutamate on the presynaptic terminals and inhibits postsynaptic excitation. However, the anti-dyskinetic effect of modulating mGluR2/3 is still unclear. In this study, rats with unilateral dopaminergic lesion were injected with L-DOPA (12 mg/kg, i.p.) for seven days, while motor behavior was correlated with in vivo electrophysiology analyzing LFP and single-cell activity in both primary motor cortex and dorsolateral striatum. Our study showed that as LID established, high γ oscillation (hγ) predominated during LID, the number of unstable responses of SPN to dopamine increased, and the coherence between these patterns of oscillation and spiking activity also increased. We found that pretreatment of NMDA receptor antagonist, amantadine 60 mg/kg, i.p. (AMAN) significantly reduced abnormal involuntary movements (AIMs), in parallel with the reduction of hγ oscillation, and more markedly with a decrease in unstable responses of SPNs. In contrast, a mGluR2/3 agonist, LY354740 12 mg/kg, i.p. (LY) significantly shortened the duration of LID but merely exhibited a weak effect in diminishing the intensity of LID or reversing SPN responses. Together results indicate that AIMs in the rat model of PD are associated with abnormal corticostriatal signaling, which could be reversed by NMDAR antagonism more efficiently than mGluR2/3 agonism.
展开更多
最新影响因子:7.046 | 期刊ISSN:0969-9961 | CiteScore:5.32 |
出版周期:Bimonthly | 是否OA:YES | 出版年份:1994 |
期刊官方网址:http://www.journals.elsevier.com/neurobiology-of-disease/
期刊投稿地址:http://ees.elsevier.com/ynbdi/default.asp?pg=preRegistration.asp
自引率:2.40% | 研究方向:医学-神经科学 |
出版地区:ENGLAND |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Register now for free access to full text articles from Neurobiology of Disease ! Neurobiology of Disease, Experimental Neurology Part B, is a major international journal at the interface between basic and clinical neuroscience. The journal provides a forum for the publication of top quality research papers on: molecular and cellular definitions of disease mechanisms, the neural systems and underpinning behavioral disorders, the genetics of inherited neurological and psychiatric diseases, nervous system aging, and findings relevant to the development of new therapies.
现在注册免费获取全文文章从神经生物学的疾病!疾病的神经生物学,实验神经学B部分,是一个主要的国际期刊在基础神经科学和临床神经科学之间的接口。该杂志为发表高质量的研究论文提供了一个论坛:疾病机制的分子和细胞定义、神经系统和支持行为障碍、遗传神经和精神疾病的遗传学、神经系统老化以及与新疗法开发相关的发现。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
NEUROSCIENCES (神经科学) 2区 |
40/261 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
187 | 157 | 30 |
引文计数(2018)
文献(2015-2017)
4291次引用
806篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Neuroscience
小类(学科):Neurology
|
#8/142
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
liting7111
研究方向:生命科学 遗传学 生物信息学 基因组学
审稿时间: 2个月内
影响因子:1.714
ISSN:1386-2073
研究方向:化学-生化研究方法
影响因子:6.088
ISSN:1933-7213
研究方向:医学-神经科学
影响因子:1.379
ISSN:0362-5664
研究方向:医学-临床神经学
影响因子:4.287
ISSN:1473-7175
研究方向:CLINICAL NEUROLOGY-PHARMACOLOGY & PHARMACY
影响因子:1.821
ISSN:1528-4336
研究方向:医学-传染病学
影响因子:2.385
ISSN:1120-009X
研究方向:医学-药学
影响因子:2.706
ISSN:1076-6294
研究方向:医学-传染病学
影响因子:4.177
ISSN:1178-6973
研究方向:-
影响因子:5.758
ISSN:0305-7453
研究方向:医学-传染病学
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
NEUROBIOLOGY OF DISEASE 投稿经验
(由下方点评分析获得,2人参与,23100人阅读)